Frontier to Report Second-Quarter 2025 Earnings on July 29, 2025
What's happening?
Frontier Communications Parent, Inc. (NASDAQ: FYBR) ('Frontier') today announced it will report its second-quarter 2025 financial results after the market closes on Tuesday, July 29, 2025.
Pending Acquisition by Verizon
As previously announced, on September 4, 2024, Verizon Communications Inc. ('Verizon') and Frontier Communications Parent, Inc. entered into a definitive agreement for Verizon to acquire Frontier (the 'transaction'). Due to the pending transaction, Frontier will not host a conference call to review quarterly results or provide a financial outlook.
About Frontier
Frontier (NASDAQ: FYBR) is the largest pure-play fiber provider in the U.S. Driven by our purpose, Building Gigabit America®, we deliver blazing-fast broadband connectivity that unlocks the potential of millions of consumers and businesses. For more information, visit www.frontier.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
25 minutes ago
- Globe and Mail
Outlook Therapeutics Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that Bob Jahr, newly appointed Chief Executive Officer, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Mr. Jahr dove deeper into what brought him to Outlook Therapeutics, how he got to where he is today and provided insight into why he is excited about the future for Outlook Therapeutics. The on-demand video webcast is now available on as well as the Events page under the Investors section of the Company's website ( About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD. In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. Jenene Thomas
National Post
25 minutes ago
- National Post
AXL teams with RSM Canada to build AI solutions for Canada's future
Article content TORONTO — AXL, a Canadian venture studio transforming world-class applied AI research into high-growth companies, and RSM Canada LLP ('RSM'), a leading global provider of assurance, tax and consulting services, have entered into a strategic collaboration. Together, the two organizations are driving innovation by challenging existing models and reimagining what's possible in professional services by integrating AI advancements with real-world business needs. Article content As part of the collaboration, RSM will serve as the exclusive provider of accounting, tax and consulting services to AXL, offering strategic guidance, compliance expertise, and growth planning support. Additionally, RSM will act as a preferred provider of these services to AXL's portfolio of startup companies. Article content RSM is also one of several leading Canadian organizations participating in AXL's AI Catalyst program, a corporate partnership initiative designed to validate and accelerate breakthrough ideas driven by real industry demand. The goal is to fast-track the commercialization of high-potential AI applications and ensure Canadian innovations are built into the country's economic future, rather than being exported before they scale. Article content 'Canada doesn't have an innovation gap, it has a commercialization gap,' says Dr. Daniel Wigdor, co-founder and CEO of AXL. 'With RSM, we're taking demand signals from the market and moving fast to turn that into scalable, enterprise-ready solutions. This is execution over hype. This is how Canada leads—not just in ideas, but in outcomes.' Article content Canada leads in AI academic research but struggles to retain its economic benefits, as much of its advancements are commercialized internationally. Article content Fewer than 20 per cent of mid-sized Canadian companies have begun adopting AI, according to the OECD, citing barriers such as limited technical talent, high costs and an uncertain return on investment. These findings are echoed in RSM's 2025 Middle Market AI Survey, which highlights similar challenges and underscores the need for practical, scalable AI solutions tailored to the middle market. Article content Meanwhile, nearly 75 per cent of AI patents from Canada's top institutes are acquired by international tech firms, with only 7 per cent remaining in the country. The United Nations also estimates that fewer than half of Canada's top AI innovations are ever patented, highlighting a critical disconnect between invention and impact. Article content By integrating real-time industry feedback, the AXL-RSM collaboration advances Canadian AI venture growth, commercialization and talent development, ensuring solutions scale domestically and drive lasting economic impact. Article content 'We're seeing incredible momentum around AI and the value it can unlock,' said Harry Blum, national managing partner at RSM Canada. 'With AXL as a strategic collaborator, we're accelerating innovation—helping businesses move beyond legacy models and positioning them to grow, compete and thrive in a future-ready economy, while embedding AI across our own solution sets.' Article content The relationship represents a direct commitment to Canada's AI ecosystem, powering homegrown innovation while reinforcing a shared commitment to helping Canadian businesses lead in the digital economy. RSM recently committed US$1 billion globally to AI, with a focus on helping middle market businesses adopt AI, especially those ready to innovate but lacking scale or resources. This initiative by RSM further aligns with AXL's vision of positioning Canada as a global leader in applied AI by bridging the gap between research and commercialization. Article content Together, AXL and RSM aim to unlock the next wave of AI-driven economic growth, bringing AI solutions that empower Canadian businesses and proving the benefit of AI not just in theory but in practice. Article content To learn more about how AXL is fuelling Canada's AI research-to-commercialization pipeline, visit their website at Article content About AXL Article content AXL is a Canadian venture studio transforming world-class research into high-growth companies that shape the future of applied AI. Led by seasoned tech entrepreneurs and applied AI experts, AXL's mission is to ensure Canada's top breakthroughs are built and scaled at home. By connecting academia with real market demand and full-stack venture creation, AXL helps Canada move from invention to impact, anchoring talent, intellectual property, and long-term economic value within the country. For more information, visit and connect with us on Article content About RSM Canada Article content RSM empowers middle market companies worldwide to take charge of change. The clients we serve are the engine of global commerce and economic growth. Our unique middle market perspective makes RSM the natural choice for growth-oriented, internationally active organizations seeking relevant insights and tailored, innovative solutions for a complex and changing world. With a global reach spanning more than 120 countries, we instill confidence in a world of change by bringing the full power of RSM to make a lasting impact on our clients, colleagues and communities. Article content RSM Canada LLP provides public accounting services and is the Canadian member firm of RSM International, a global network of independent assurance, tax and consulting firms. RSM Canada Consulting LP provides consulting services and is an affiliate of RSM US LLP, a member firm of RSM International. For more information visit like us on Facebook, follow us on X and/or connect with us on LinkedIn. Article content Article content Article content Article content Contacts Article content For media inquiries: Article content Article content Article content Article content
Globe and Mail
25 minutes ago
- Globe and Mail
Palisade Bio Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand Carlsbad, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ('Palisade', 'Palisade Bio', or the 'Company'), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced JD Finley Chief Executive Officer of Palisade Bio, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Mr. Finley dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Events page under the Investors section of the Company's website ( About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to
